- /
- Supported exchanges
- / US
- / GRCE.NASDAQ
Grace Therapeutics, Inc. (GRCE NASDAQ) stock market data APIs
Grace Therapeutics, Inc. Financial Data Overview
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray of betamethasone to improve neurological symptoms of Ataxia-Telangiectasia (A-T) and GTX-101, a topical bioadhesive film-forming polymer for the treatment of pain associated with postherpetic neuralgia (PHN). The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. Grace Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Grace Therapeutics, Inc. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Grace Therapeutics, Inc. data using free add-ons & libraries
Get Grace Therapeutics, Inc. Fundamental Data
Grace Therapeutics, Inc. Fundamental data includes:
- Net Revenue:
- EBITDA: -11 241 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get Grace Therapeutics, Inc. Earnings data
Corporate Events Calendar & News package for
What’s included:
- Latest Release: 2026-02-12
- EPS/Forecast: -0.39
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Grace Therapeutics, Inc. News
New
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Grace Therapeutics, Inc. - GRCE
NEW YORK, May 19, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Grace Therapeutics, Inc. (“Grace” or the “Company”) (NASDAQ: GRCE). Such investors ...
Weekly Buzz: SNY, REGN Get FDA Nod; It's A No For ABBV, GRCE; LLY Acquires Kelonia
(RTTNews) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic ar...
FDA Issues CRL To Grace Therapeutics For GTx-104 In ASAH; Stock Down
(RTTNews) - Grace Therapeutics, Inc. (GRCE) announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the firm's New Drug Application (NDA) for GTx-104 f...
Sector Update: Health Care Stocks Edge Lower Late Afternoon
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscri...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.